A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

NCT05086445 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the investigational drug LY3502970 in Japanese adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 62 people

Who can join Ages 20–70 · all sexes

Timeline Started 2021-11 · est. completion 2022-09

Where 5 sites · Japan

What this study is testing ClinicalTrials.gov NCT05086445 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.

Treatments tested

LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05086445 ↗